VICAL INC
Form SC 13G/A
February 01, 2019
<b>UNITED STATES</b>

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**SCHEDULE 13G** 

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No.  $1)^1$ 

Vical Incorporated (Name of Issuer)

Common Stock, \$0.01 par value (Title of Class of Securities)

925602203 (CUSIP Number)

December 31, 2018 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

<sup>1</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

1	NAME OF REPORTING PERSON	
2	Biotechi Fund, L. CHECK TH APPROPRI BOX IF A MEMBER ( GROUP	IE ATE (a) OF A
3	SEC USE C	(b) ONLY
4	CITIZENSI OF ORGAN	HIP OR PLACE NIZATION
	Delawar	re
NUMBER OF	5	SOLE VOTING POWER
SHARES BENEFICIALLY	7	0 shares
OWNED BY	6	SHARED VOTING POWER
EACH		
REPORTING		1,336,100 (1)
PERSON WITH	7	SOLE DISPOSITIVE POWER
	8	0 shares SHARED DISPOSITIVE POWER
		1,336,100
9	BENEFICIA	ATE AMOUNT ALLY OWNED REPORTING
10	1,336,10	00 (1)

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW (9)

5.9% (1)

12 TYPE OF REPORTING PERSON

PN

(1) Includes 992,750 shares of Common Stock currently issuable upon the exercise of the Warrants (as defined herein). Excludes 2,598,039 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation (as defined herein), which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock.

# CUSIP No. 925602203

1	NAME OF REPORTING PERSON	
	Fund II, CHECK TH APPROPRI	E ATE
2	BOX IF A MEMBER O GROUP	(a) OF A
		(b)
3	SEC USE O	NLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware	e
		SOLE
NUMBER OF	5	VOTING
SHARES BENEFICIALLY	,	POWER  0 shares
DENEFICIALLI		SHARED
OWNED BY	6	VOTING
		POWER
EACH		705 (22
REPORTING		795,623
		SOLE
PERSON WITH	7	DISPOSITIVE
		POWER
		0 shares
		SHARED
	8	DISPOSITIVE
		POWER
		795,623
	AGGREGA	TE AMOUNT
0		ALLY OWNED
9		REPORTING
	PERSON	
	795,623	(1)
10	CHECK BO	
	THE AGGR	

AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW (9)

3.7% (1)

12 TYPE OF REPORTING PERSON

PN

(1) Excludes 2,296,089 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock.

1	NAME OF PERSON	REPORTING
2		ATE (a)
3	SEC USE C	
4	CITIZENSI OF ORGAN	HIP OR PLACE NIZATION
	Cayman	Islands
NUMBER OF	5	SOLE VOTING POWER
SHARES BENEFICIALLY OWNED BY	6	0 shares SHARED VOTING POWER
EACH		POWER
REPORTING		106,239
PERSON WITH	7	SOLE DISPOSITIVE POWER
	8	0 shares SHARED DISPOSITIVE POWER
		106,239
9	BENEFICIA	TE AMOUNT ALLY OWNED REPORTING
	106,239	(1)

10 CHECK BOX IF
THE AGGREGATE
AMOUNT IN ROW
(9) EXCLUDES
CERTAIN
SHARES

PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW (9)

Less than 1% (1)

12 TYPE OF REPORTING PERSON

PN

(1) Excludes 615,779 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock.

1	NAME OF REPORTING PERSON	
2	BVF Par CHECK TH APPROPRI BOX IF A MEMBER O GROUP	ATE (a)
		(b)
3	SEC USE O	NLY
4	CITIZENSI OF ORGAN	HIP OR PLACE NIZATION
	Cayman	
NUMBER OF	5	SOLE VOTING POWER
SHARES BENEFICIALLY	7	0 shares
OWNED BY	6	SHARED VOTING POWER
EACH		
REPORTING		106,239
PERSON WITH	7	SOLE DISPOSITIVE POWER
	8	0 shares SHARED DISPOSITIVE POWER
		106,239
9	BENEFICIA	TE AMOUNT ALLY OWNED REPORTING
10	106,239	(1)

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW (9)

Less than 1% <sup>(1)</sup> TYPE OF REPORTING PERSON

CO

(1) Excludes 615,779 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock.

5

1	NAME OF REPORTING PERSON	
2	BVF Par CHECK TH APPROPRL BOX IF A MEMBER O GROUP	ATE (a)
		(b)
3	SEC USE O	NLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware	e
NUMBER OF	5	SOLE VOTING POWER
SHARES BENEFICIALLY		0 shares SHARED
OWNED BY	6	VOTING POWER
EACH		
REPORTING		2,278,598
PERSON WITH	7	SOLE DISPOSITIVE POWER
	8	0 shares SHARED DISPOSITIVE POWER
		2,278,598 (1)
9	BENEFICIA	TE AMOUNT ALLY OWNED REPORTING
10	2,278,598 <sup>(1)</sup> CHECK BOX IF	

THE AGGREGATE

AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW (9)

9.99% (1)

12 TYPE OF REPORTING PERSON

PN, IA

1 11, 17

(1) Includes 992,750 shares of Common Stock currently issuable upon the exercise of the Warrants. Excludes 6,241,535 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock.

1	NAME OF REPORTING PERSON	
2	BVF Inc CHECK TH APPROPRI BOX IF A MEMBER O GROUP	IE ATE (a)
_		,
3	SEC USE O	NLY
4	CITIZENSI OF ORGAN	HIP OR PLACE NIZATION
	Delawar	e
NUMBER OF	5	SOLE VOTING POWER
SHARES BENEFICIALLY	7	0 shares
OWNED BY	6	SHARED VOTING POWER
EACH		
REPORTING		2,278,598 <sub>(1)</sub>
PERSON WITH	7	SOLE DISPOSITIVE POWER
	8	0 shares SHARED DISPOSITIVE POWER
		2,278,598 <sub>(1)</sub>
9	BENEFICIA	TE AMOUNT ALLY OWNED REPORTING
10	2,278,59 CHECK BC THE AGGR	X IF

AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW (9)

9.99% (1)

TYPE OF REPORTING

PERSON

CO

(1) Includes 992,750 shares of Common Stock currently issuable upon the exercise of the Warrants. Excludes 6,241,535 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock.

1	NAME OF REPORTING PERSON	
2	Mark N. CHECK TH APPROPRI BOX IF A MEMBER O GROUP	ATE (a)
		(b)
3	SEC USE O	NLY
4	CITIZENSI OF ORGAN	HIP OR PLACE VIZATION
	United S	tates
NUMBER OF	5	SOLE VOTING POWER
SHARES		FOWER
BENEFICIALLY	<i>7</i>	0 shares
OWNED BY	6	SHARED VOTING
EACH		POWER
REPORTING		2,278,598
PERSON WITH	7	SOLE DISPOSITIVE POWER
	8	0 shares SHARED DISPOSITIVE POWER
		2,278,598 (1)
9	BENEFICIA	TE AMOUNT ALLY OWNED REPORTING
10	2,278,59 CHECK BC THE AGGR	X IF

AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW (9)

9.99% (1)

12 TYPE OF REPORTING PERSON

IN

(1) Includes 992,750 shares of Common Stock currently issuable upon the exercise of the Warrants. Excludes 6,241,535 shares of Common Stock underlying the Warrants that are not exercisable due to the Beneficial Ownership Limitation, which provides that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares outstanding of Common Stock.

CUSIP No. 925602203

Grand Cayman, KY1-1104

Name of Issuer: Item 1(a). Vical Incorporated, a Delaware corporation (the "Issuer"). Item 1(b). Address of Issuer's Principal Executive Offices: 10390 Pacific Center Court San Diego, California 92121 Item 2(a). Name of Person Filing Item 2(b). Address of Principal Business Office or, if None, Residence Item 2(c). Citizenship Biotechnology Value Fund, L.P. ("BVF") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware Biotechnology Value Fund II, L.P. ("BVF2") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware Biotechnology Value Trading Fund OS LP ("Trading Fund OS") PO Box 309 Ugland House

Cayman Islands
Citizenship: Cayman Islands
BVF Partners OS Ltd. ("Partners OS")
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
Citizenship: Cayman Islands
BVF Partners L.P. ("Partners")
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
BVF Inc.
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: Delaware
Mark N. Lampert ("Mr. Lampert")
44 Montgomery St., 40th Floor
San Francisco, California 94104
Citizenship: United States
Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
9

CUSIP No. 925602203

Item 2(d).	Title of Class of Securities:	
Common Stock, \$0.01 par value (the "Common Stock").		
Item 2(e).	CUSIP Number:	
925602203		
Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b	o), or 13d-2(b) or (c), Check Whether the Person Filing is a:	
/x/Not applicable.		
(a)// Broker or dealer registered under Section 15 of the	Exchange Act.	
(b)// Bank as defined in Section 3(a)(6) of the Exchange	Act.	
(c)// Insurance company as defined in Section 3(a)(19) of the Exchange Act.		
(d)// Investment company registered under Section 8 of	the Investment Company Act.	
(e)// An investment adviser in accordance with Rule 13c	d-1(b)(1)(ii)(E).	
(f) // An employee benefit plan or endowment fund in ac	ecordance with Rule 13d-1(b)(1)(ii)(F).	
(g)// A parent holding company or control person in accordance	ordance with Rule 13d-1(b)(1)(ii)(G).	
(h)// A savings association as defined in Section 3(b) of	the Federal Deposit Insurance Act.	
(i) // A church plan that is excluded from the definition of Investment Company Act.	of an investment company under Section 3(c)(14) of the	
(j) // Group, in accordance with Rule 13d-1(b)(1)(ii)(J).		
(k)// Group, in accordance with Rule 240.13d-1(b)(1)(ii) Rule 240.13d-1(b)(1)(ii)(J), please specify the type	o(K). If filing as a non-U.S. institution in accordance with of institution:	
Item 4.	Ownership	

(a) Amount beneficially owned:

As of the close of business on December 31, 2018, the Reporting Persons held 7,234,285 warrants, exercisable for an aggregate of 7,234,285 shares of Common Stock (the "Warrants"). Such Warrants have an initial exercise price of \$0.01 per share, subject to adjustment pursuant to the terms of the Warrants. The Warrants are only exercisable to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would not beneficially own more than 9.99% of the outstanding Common Stock after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the Warrants (the "Beneficial Ownership Limitation"). As of December 31, 2018, the Beneficial Ownership Limitation limits the aggregate exercise of the Warrants by the Reporting Persons to 992,750 out of the 7,234,285 shares of Common Stock underlying the Warrants owned by the Reporting Persons in the aggregate. In providing beneficial ownership described herein, the Reporting Persons have assumed 992,750 of the 3,590,789 Warrants owned by BVF would be exercised. BVF2 holds Warrants to purchase 2,296,089 additional shares which are excluded herein as a result of the Beneficial Ownership Limitation. The Reporting Persons through certain Partners managed accounts (the "Partners Managed Accounts") holds Warrants to purchase 731,628 additional shares which are excluded herein as a result of the Beneficial Ownership Limitation.

CUSIP No. 925602203

As of the close of business on December 31, 2018 (i) BVF beneficially owned 1,336,100 shares of Common Stock, including 992,750 shares of Common Stock underlying the Warrants that are currently exercisable, (ii) BVF2 beneficially owned 795,623 shares of Common Stock, and (iii) Trading Fund OS beneficially owned 106,239 shares of Common Stock.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 106,239 shares of Common Stock beneficially owned by Trading Fund OS.

Partners, as the general partner of BVF, BVF2, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 2,278,598 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, including 40,636 shares of Common Stock held in the Partners Managed Accounts.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 2,278,598 shares of Common Stock beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 2,278,598 shares of Common Stock beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Partners OS disclaims beneficial ownership of the shares of Common Stock beneficially owned by Trading Fund OS. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Accounts, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on a denominator which is the sum of: (i) 21,816,041 shares of Common Stock outstanding, which is the total number of share of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 29, 2018 and (ii) the 992,750 shares of Common Stock underlying certain Warrants, as applicable.

As of the close of business on December 31, 2018 (i) BVF beneficially owned approximately 5.9% of the outstanding shares of Common Stock, (ii) BVF2 beneficially owned approximately 3.7% of the outstanding shares of Common Stock, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding shares of Common Stock, (iv) Partners OS may be deemed to beneficially own less than 1% of the outstanding shares of Common Stock, and (v) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding shares of Common Stock (less than 1% of the outstanding shares of Common Stock is held in the Partners Managed Accounts).

CUSIP No. 925602203

(c)	Number of shares as to which such person has:
(i)	Sole power to vote or to direct the vote
See Cover Pages Items 5-9.	
(ii)	Shared power to vote or to direct the vote
See Cover Pages Items 5-9.	
(iii)	Sole power to dispose or to direct the disposition of
See Cover Pages Items 5-9.	
(iv)	Shared power to dispose or to direct the disposition of
See Cover Pages Items 5-9.	
Item 5.	Ownership of Five Percent or Less of a Class.
Not Applicable.	
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	npert share voting and dispositive power over the shares of Common Stock VF2, Trading Fund OS, and the Partners Managed Accounts.

Item 7.	em Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parel Holding Company or Control Person.				
Not A	applicable.				
	Item 8.	Identification and Classification of Members of the Group.			
See E	See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on November 17, 2017.				
	Item 9.	Notice of Dissolution of Group.			
Not A	applicable.				
	Item 10	Certifications.			

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

### CUSIP No. 925602203

#### **SIGNATURE**

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 1, 2019

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By:/s/ Mark N. Lampert

Mark N. Lampert

President

BVF INC.

By:/s/ Mark N. Lampert Mark N. Lampert

President

/s/ Mark N. Lampert MARK N. LAMPERT

### BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By:/s/ Mark N. Lampert Mark N. Lampert President

### BVF PARTNERS L.P.

By: BVF Inc., its general partner

By:/s/ Mark N. Lampert Mark N. Lampert President

### BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member

By: BVF Inc., its general partner

By:/s/ Mark N. Lampert Mark N. Lampert President

Biotechnology Value Trading Fund OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By:/s/ Mark N. Lampert Mark N. Lampert President